Roivant Sciences Ltd. (ROIV)
| Market Cap | 7.62B |
| Revenue (ttm) | 122.59M |
| Net Income (ttm) | -116.62M |
| Shares Out | 713.55M |
| EPS (ttm) | -0.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,954,358 |
| Open | 10.72 |
| Previous Close | 10.72 |
| Day's Range | 10.67 - 10.86 |
| 52-Week Range | 9.76 - 13.06 |
| Beta | 1.25 |
| Analysts | Strong Buy |
| Price Target | 17.93 (+67.88%) |
| Earnings Date | Feb 10, 2025 |
About ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human mon... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price forecast is $17.93, which is an increase of 67.88% from the latest price.
News
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger ...
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a ...
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatme...
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics Zest is initially focused on treating the millions ...
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Feb...
Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Roivant, a global biopharmaceutical company that aims to improve the lives of patients by...
Roivant Sciences: A Biotech Growth Play With Major Ambitions
Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT...
Roivant's lung disease drug fails mid-stage trial
Roivant said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of lung disease.
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimm...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, No...
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant ha...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
BASEL, Switzerland and LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-clas...
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pulmovant, a Roivant (Nasdaq: ROIV) company, today announced the presentation of data from the proof-of-concept Phase 1b ATMOS1 study during the ERS ...
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much ...
Roivant Provides Update on Graves' Disease Development Program
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...
Top Stocks Near Their 200-Day SMA
The 200-day Simple Moving Average is an important technical indicator that can signal potential bullish sentiment and breakout opportunities for stocks. The 200-day SMA can also act as support or resi...
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to ...
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference ...
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered al...
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Geneva...
Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Conference Call May 30, 2024 8:00 AM ET Company Participants Abby Beier - Principal, Strategic Finance Matt Gline - Chief Executive Officer Frank ...
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, an...